bpc-157 case report human adverse event and the Difference Between an Evidence Gap and a BPC-157: Miracle Healing Peptide or

In order to evaluate substantial clinical improvement over currently available treatments to meet the transitional pass-through payment criterion at 419.66(c)(2), we stated that we consider supporting evidence, preferably published peer-reviewed clinical trials, that demonstrates improved clinical outcomes, such as reduction in mortality, complications, subsequent interventions, future hospitalizations, recovery time, pain, or a more rapid beneficial resolution of the disease process comparing the nominated device to the standard of care (88 FR 81733)

J Exp Bot 69:34013411

510% weight loss is considered clinically meaningful with pharmacotherapy

Plasma half-life is about 159-195 hours, or roughly 6.6-8.1 days

A shot of reality WHICH BRINGS US back to Juan Leija, the personal trainer who turned to BPC-157 to deal with his worsening elbow pain